Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sumitomo Chemical

Andy Lee has been appointed president and CEO of Sumitomo Chemical's US-based subsidiaries, Valent USA Corporation (Walnut Creek, California) and Valent BioSciences (Libertyville, Illinois), from the end of March when Michael Donaldson retires. Mr Donaldson has been with Sumitomo for 14 years and became president of the two Valent businesses in 2009 (Agrow No 561, p 19). He also assumed the presidency of Pace International (Seattle, Washington) following its acquisition by Valent BioSciences in December 2012 (Agrow No 655, p 2). Valent BioSciences' executive vice-president and COO, Ted Melnik, will assume the role of president of Pace International on Mr Donaldson's retirement. Valent USA's vice-president of sales, Matt Plitt, will take over from Mr Lee as executive vice-president and COO of that business. After retirement, Mr Donaldson will serve as an adviser to the president of Sumitomo's health and crop sciences sector, Ray Nishimoto.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG001160

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel